logo
logo
Evolent Health, Inc.

Evolent Health, Inc.

NYSE•EVH
CEO: Mr. Seth Barrie Blackley
セクター: Healthcare
業種: Medical - Healthcare Information Services
上場日: 2015-06-05
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients. In addition, the company provides holistic total cost of care management. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
連絡先情報
1812 N. Moore Street, Suite 1705, Arlington, VA, 22209, United States
571-389-6000
www.evolent.com
時価総額
$316.60M
PER (TTM)
-2.4
30
配当利回り
--
52週高値
$12.07
52週安値
$2.69
52週レンジ
0%
順位53Top 76.1%
2.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 2.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$479.53M-22.83%
直近4四半期の推移

EPS

-$0.24-11.11%
直近4四半期の推移

フリーCF

$6.85M-44.67%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Operating Loss Narrows Significantly Operating loss improved $19.982M to $(1.9M) for nine months 2025; 91.3% reduction in loss magnitude compared to prior year.
Liquidity Position Remains Strong Cash and equivalents total $116.7M as of September 30, 2025; sufficient liquidity projected to meet working capital needs for twelve months.
Debt Restructuring Completed Exchanged $175.0M Series A Preferred Stock for new second lien term loan facility on August 7, 2025, simplifying capital structure.
Goodwill Unimpaired Post-Sale Interim goodwill assessment confirmed fair value exceeded carrying value following the agreed sale of ECP Holding Company subsidiary.

リスク要因

Revenue Declined Substantially Nine-month revenue dropped $500.7M (26.2%) due to major contractual updates and narrowing scope with key Performance Suite customers.
High Partner Revenue Concentration Significant revenue concentration exists; loss or renegotiation with largest partners, like Molina Healthcare, could materially impact results.
Regulatory Uncertainty High OBBBA legislation introduces changes to Medicaid/Medicare potentially reducing covered membership and negatively impacting future revenue.
Debt Service Obligations Increase Floating rate debt subject to SOFR increases could raise annual interest expense by $4.53M per 1% SOFR increase.

見通し

Divestiture Closing Anticipated Anticipate closing sale of ECP Holding Company in Q4 2025, allocating $61.9M goodwill to the transaction based on enterprise value.
ACA Membership Expected Lower Industry expects lower ACA Health Exchange membership in 2026 following scheduled premium tax credit expirations at year-end 2025.
Intangible Amortization Schedule Future intangible asset amortization totals $623.7M, with $16.1M expected in the remainder of 2025 based on current estimates.
Future Financing Needs Possible May seek external financing for expansion, acquisitions, or debt refinancing depending on future capital requirements and market conditions.

同業比較

売上高 (TTM)

AMN Healthcare Services, Inc.AMN
$2.72B
-11.4%
Evolent Health, Inc.EVH
$2.05B
-16.6%
Tandem Diabetes Care, Inc.TNDM
$1.01B
+3.4%

粗利益率 (最新四半期)

Xencor, Inc.XNCR
100.0%
+0.0pp
Phathom Pharmaceuticals, Inc.PHAT
87.5%
+1.9pp
Kura Oncology, Inc.KURA
84.5%
+0.0pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
ANAB$1.39B-17.3-1101.2%98.1%
TNDM$1.32B-6.5-118.8%51.4%
EYPT$1.14B-4.7-76.1%8.5%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
-9.5%
成長鈍化
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年2月19日
|
EPS:$0.06
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $479.53M-22.8%
    |
    EPS: $-0.24-11.1%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月11日|
    売上高: $444.33M-31.3%
    |
    EPS: $-0.44+689.9%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月9日|
    売上高: $483.65M-24.4%
    |
    EPS: $-0.63+186.4%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月21日|
    売上高: $2.55B+30.1%
    |
    EPS: $-0.81+36.7%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $621.40M+21.6%
    |
    EPS: $-0.27-10.0%
    予想を下回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月9日|
    売上高: $647.15M+37.9%
    |
    EPS: $-0.06-82.0%
    予想を下回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $639.65M+49.6%
    |
    EPS: $-0.22+15.8%
    予想を下回る

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月23日|
    売上高: $1.96B+45.3%
    |
    EPS: $-1.28-540.0%
    予想を下回る